Anne Flint

Novo Nordisk (Denmark) — Denmark

Medicine · Health Sciences

40h-index10.9kcitations81works16.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(28), Diet and metabolism studies(28), Metabolism, Diabetes, and Cancer(21), Obesity, Physical Activity, Diet(15), Regulation of Appetite and Obesity(14)

Publications81 total

PT15 Development of the Eating Drivers Diary (EDDY): A Novel Patient-Reported Outcome Measure for Use in Clinical Trials of Medications for Weight Reduction
Value in Health·2025
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
The Lancet·2025· 33 cited
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply
Alimentary Pharmacology & Therapeutics·2021Open Access
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Alimentary Pharmacology & Therapeutics·2021· 195 citedOpen Access
Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data
Advances in Therapy·2020· 4 citedOpen Access
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
Diabetes Therapy·2019· 35 citedOpen Access
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Diabetes Therapy·2018· 37 citedOpen Access
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Diabetes Therapy·2018· 16 citedOpen Access
Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Diabetes Obesity and Metabolism·2018· 45 citedOpen Access
Bewertung der Semaglutid-Dosierungen bei Typ 2 Diabetes auf Grundlage von Populationspharmakokinetik und Expositions-Response
Diabetologie und Stoffwechsel·2018
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Advances in Therapy·2018· 26 citedOpen Access
Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
Diabetes Obesity and Metabolism·2017· 208 citedOpen Access
Cover Image, Volume 19, Issue 9
Diabetes Obesity and Metabolism·2017
P5349Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects
European Heart Journal·2017· 2 citedOpen Access
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
Diabetologia·2017· 104 citedOpen Access
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Clinical Pharmacokinetics·2017· 115 citedOpen Access
Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Diabetes Obesity and Metabolism·2017· 583 citedOpen Access
Le semaglutide entraîne une réduction de l’appétit et de l’apport énergétique à l’origine d’une perte de poids chez les sujets obèses
Diabetes & Metabolism·2017
Semaglutide reduces appetite and energy intake, improves control of eating and provides weight loss in subjects with obesity
Diabetes Research and Clinical Practice·2016· 1 cited
The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes
Diabetes Research and Clinical Practice·2016· 7 cited
page 1 of 5Next →

Frequent Co-authors

Arne Astrup(24), Anne Raben(20), Jens J. Holst(14), Birgitte Sloth(7), Christoph Kapitza(7), Inge Tetens(6), John E. Blundell(4), Steen H. Ingwersen(4), Charlotte Hindsberger(4), Milan Zdravković(4), Mads Axelsen(3), Inger Krog-Mikkelsen(3), Nikolaj Ture Gregersen(3), Bente K. Møller(3), B. Møller(3), Kristin C. Carlsson Petri(3), Jeppe Zacho(3), Rune Viig Overgaard(3), Camilla Verdich(2), Trine Kvist(2)